Evaluation in mice of Brucella ovis attenuated mutants for use as live vaccines against B. ovis infection

Pilar Sancho, Carmen Tejedor, Rebeca S Sidhu-Muñoz, Luis Fernández-Lago, Nieves Vizcaíno

To cite this version:

Pilar Sancho, Carmen Tejedor, Rebeca S Sidhu-Muñoz, Luis Fernández-Lago, Nieves Vizcaíno. Evaluation in mice of Brucella ovis attenuated mutants for use as live vaccines against B. ovis infection. Veterinary Research, BioMed Central, 2014, 45 (1), pp.61. 10.1186/1297-9716-45-61 . hal-01290642

HAL Id: hal-01290642
https://hal.archives-ouvertes.fr/hal-01290642

Submitted on 18 Mar 2016

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Evaluation in mice of *Brucella ovis* attenuated mutants for use as live vaccines against *B. ovis* infection

Pilar Sancho¹, Carmen Tejedor¹, Rebeca S Sidhu-Muñoz¹,², Luis Fernández-Lago¹,² and Nieves Vizcaíno¹,²*

**Abstract**

*Brucella ovis* causes ram contagious epididymitis, a disease for which a specific vaccine is lacking. Attenuated *Brucella melitensis* Rev 1, used as vaccine against ovine and caprine brucellosis caused by *B. melitensis*, is also considered the best vaccine available for the prophylaxis of *B. ovis* infection, but its use for this purpose has serious drawbacks. In this work, two previously characterized *B. ovis* attenuated mutants (Δomp25d and Δomp22) were evaluated in mice, in comparison with *B. melitensis* Rev 1, as vaccines against *B. ovis*. Similarities, but also significant differences, were found regarding the immune response induced by the three vaccines. Mice vaccinated with the *B. ovis* mutants developed anti-*B. ovis* antibodies in serum of the IgG1, IgG2a, and IgG2b subclasses and their levels were higher than those observed in Rev 1-vaccinated mice. After an antigen stimulus with *B. ovis* cells, splenocytes obtained from all vaccinated mice secreted similar levels of TNF-α and IL12(p40) and remarkably high amounts of IFN-γ, IL-1, and IL-12, while IL-10, an anti-inflammatory cytokine, was significantly more abundant in Rev 1-vaccinated mice. Additionally, the *B. ovis* mutants showed appropriate persistence, limited splenomegaly and protective efficacy against *B. ovis* similar to that observed with *B. melitensis* Rev 1. These characteristics encourage their evaluation in the natural host as homologous vaccines for the specific prophylaxis of *B. ovis* infection.

**Introduction**

Brucellosis caused by *Brucella ovis* mainly induces chronic epididymitis and orchitis in rams. The disease is widely distributed and constitutes one of the most important causes of reproductive failure in sheep [1]. In addition to a reduction in male fertility, *B. ovis* induces occasional abortions in ewes and increases the risk of perinatal mortality and low weight in lambs, thus having an important economic impact in the livestock sector [1].

*Brucella* strains are smooth (S) or rough (R), depending on the presence or absence of O-poly saccharide (O-PS) chains in the lipopolysaccharide (LPS) respectively. Other outer membrane (OM) components -such as OM proteins (OMPs) or the core and lipid A of LPS- are masked by O-PS in S strains, while in R brucellae, such as *B. ovis*, they are exposed on the bacterial surface [2]. In infected animals and humans, the O-PS chains induce a strong antibody response that constitutes the basis for the serological diagnosis of infections caused by *S Brucella* strains [2]. *Brucella melitensis* Rev 1 is an S live attenuated strain currently used for vaccination campaigns against ovine and caprine brucellosis, which is almost exclusively caused by *B. melitensis* and *B. ovis*. It is also considered the best vaccine available for the prophylaxis of *B. ovis* infection despite being mainly used for preventing *B. melitensis* infection [3-7]. However, several drawbacks are associated with Rev 1 vaccine, such as its variable efficacy, the induction of antibodies against S-LPS interfering with the diagnosis of brucellosis caused by *B. melitensis* and other *S brucellae*, the ability to induce human infections and abortions in animals and its resistance to streptomycin [5,8,9]. Additionally, due to its serological cross-reactivity with other *S Brucella* strains, it is banned in countries where *B. melitensis* has been eradicated, some of which are...
important sheep producers and where *B. ovis* infection constitute a serious problem. Therefore, the development of a new vaccine able to substitute *B. melitensis* Rev 1 strain in the prophylaxis of *B. ovis* infection is of great interest.

Subcellular vaccines based on the hot saline extract (HS) of *B. ovis* -mainly composed of R-LPS and OMPs- have been extensively analyzed in mice and rams but their protective activity is limited [10-14]. Among these vaccines, HS encapsulated in microparticles has provided the best results in terms of protection [12]. R-LPS and/or recombinant proteins, either as purified antigens or as DNA vaccines requiring repeated inoculations, have also been assayed, with different success rates [13-17]. Considering that the best vaccines available against brucellosis caused by *S. suis* strains are homologous, the development of an *R. prowazekii* attenuated vaccine strain seems to be an interesting approach for the control of *B. ovis* infection.

In light of the above, the aim of this work was to evaluate the immunogenicity and protective activity against *B. ovis* infection of two *B. ovis* attenuated mutants obtained previously by inactivation of the genes coding for Omp25d and Omp22 [19], two OMPs of the Omp25/Omp31 family [20,21]. Considering that routine analysis of *Brucella* vaccines in the natural host is precluded due to economical and practical difficulties [22], the murine model was selected for this purpose since it is proposed by the World Organisation for Animal Health (OIE) as a method for the evaluation of *Brucella* vaccines administered in sheep [23] and it is currently used in brucellosis research for the assessment of the protective activity of vaccines [22,24]. Additionally, a good correlation between the mouse model and sheep has been observed for other *Brucella* vaccines [25] and the *B. ovis* attenuated mutants have been analyzed in parallel with *B. melitensis* Rev 1 -the attenuated strain used in official vaccination campaigns against sheep brucellosis [3,23]- that constitutes a control of recognized vaccine efficacy in the natural host.

**Materials and methods**

**Bacterial strains and culture conditions**

The *Brucella* strains used in this work are shown in Table 1. The R virulent *B. ovis* PA strain and smooth (S) attenuated *B. melitensis* Rev 1 classical vaccine were obtained from the Institut National de la Recherche Agronomique, Nouzilly, France. Attenuated *B. ovis* PNV25dA (Δomp25d) and *B. ovis* PNV22A (Δomp22) are mutant strains derived from virulent *B. ovis* PA [19]. They were obtained previously by substitution of *omp25d* or *omp22*, respectively, by a kanamycin (Kan) resistance gene [19].

All *Brucella* strains were propagated in tryptic soy agar (Prondisa-Laboratorios Conda, Torrejón de Ardoz, Spain) supplemented with 0.3% yeast extract (Prondisa-Laboratorios Conda) and 5% horse serum (Gibco-Life Technologies, Grand Island, USA) (TSA-YE-HS). When appropriate, depending on the resistance profile of each *Brucella* strain (Table 1), streptomycin (Strep) or Kan (Sigma-Aldrich, St. Louis, USA) was added to TSA-YE-HS medium to a final concentration of 50 μg/mL. Bacteria were incubated at 37 °C in a 5% CO2 atmosphere.

**Mice and inoculation procedure**

Female 6-week-old BALB/c mice (Charles River Laboratories, Chatillon-sur-Chalaronne, France), received at our laboratory one week previously, were used. They were randomly distributed into experimental groups and kept with water and food *ad libitum* in the animal experimentation facilities of the University of Salamanca (registration number PAE SA-001). Procedures with mice were designed according to Spanish and European legislation regarding the use of animals in research (RD 1201/05 and directive 2010/63/UE).

Vaccination and challenge with *Brucella* strains were performed by intraperitoneal inoculation of bacterial suspensions in phosphate-buffered saline (PBS; pH 7.2) prepared from fresh cultures incubated for 44 h. The number of colony-forming units per mL (CFU/mL) was estimated by optical density (OD) readings at 600 nm (OD600) and the exact doses administered were determined retrospectively by triplicate plating of the properly diluted inocula on TSA-YE-HS.

**Immunization of mice and sample collection for evaluation of the immune response and vaccine strain persistence**

Mice were inoculated with PBS (unvaccinated control), with the *B. melitensis* Rev 1 classical vaccine (10⁵ CFU), or with the Δomp25d (10⁷ CFU) or Δomp22 (10⁸ CFU) mutants of *B. ovis* PA. The dose of vaccination for *B. melitensis* Rev 1 was that commonly used for vaccine

**Table 1 Brucella strains used in this work**

| Strain          | Origin* | Virulence (relevant genotype) | LPS phenotype | Relevant antibiotic resistance |
|-----------------|---------|------------------------------|---------------|-------------------------------|
| *B. melitensis* Rev 1 | BCCN V4a | Classical attenuated vaccine | Smooth        | Streptomycin                 |
| *B. ovis* PA    | BCCN 76-250 | Virulent strain             | Rough         | -                             |
| *B. ovis* PNV25dA | [19] | Recombinant *B. ovis* PA attenuated mutant (Δomp25d) | Rough         | Kanamycin                     |
| *B. ovis* PNV22A | [19] | Recombinant *B. ovis* PA attenuated mutant (Δomp22) | Rough         | Kanamycin                     |

*BCCN, Brucella Culture Collection, Nouzilly, France.
studies in mice [22], while the vaccination doses for the \textit{B. ovis} attenuated mutants were selected according to previous results of spleen colonization when they were inoculated at a dose of $5 \times 10^6$ CFU/mice [19] and taking into account vaccine studies with other \textit{Brucella} species [22]. Thus, considering that the \textit{omp22} mutant was severely attenuated in that previous study [19], the dose of $10^8$ CFU/mice was selected to analyze its vaccine properties, while vaccination with the \textit{omp25d} mutant -that showed a reduced persistence but a high level of spleen colonization at week 1 post-inoculation (pi) (about 2 log units higher than the parental strain) [19]- was performed at a dose of $10^7$ CFU/mice.

Sera for analysis of the antibody response were obtained from submandibular blood extracted from five mice per group at selected time-points. The same mice were then euthanized and their spleens isolated in order to determine both the CFU number of the vaccine strain (persistence assay) and the cytokine profile.

To evaluate the ability of splenocytes from vaccinated mice to secrete cytokines in response to a stimulus with heat-inactivated \textit{B. ovis} PA whole cells, five mice per group were immunized as described above and their spleens were removed 28 days later for further ex vivo analysis of spleen cell cultures, as detailed below.

**Evaluation of vaccine strain persistence**

Persistence of the vaccine strains in mice was investigated by determining the bacterial CFU in spleen at 1, 3, 7, 14, 21, 28 and 49 days post-inoculation (dpi). At each selected pi time-point, spleens from five mice per group were weighed and individually homogenized in 9 vol of Hanks’ balanced solution (Gibco-Life Technologies). Ten-fold serial dilutions were plated onto TSA-YE-HS to determine bacterial counts. The results were expressed as means ± SD (n = 5) of the log CFU/spleen for each strain. For each vaccination group, the mean ± SD (n = 5) of the spleen weight in grams was also calculated.

**Evaluation of the antibody response in serum against whole cells of \textit{B. ovis}**

Serum immunoglobulin (Ig) G (IgG) titers in immunized mice were determined by indirect enzyme-linked immunosorbent assay (i-ELISA) at 1, 3, 7, 14, 21, and 28 dpi (pre-challenge period in protection experiments). Plates (96-well Maxisorp, Nunc-Thermo Fisher Scientific, Roskilde, Denmark) were coated by overnight incubation with 100 $\mu$L of \textit{B. ovis} PA suspensions (OD$_{600}$ = 1) prepared in PBS from heat-inactivated (1 h, 65 °C) fresh cultures (44 h of growth). The wells were then incubated sequentially with 5% skim milk in PBS (30 min at 37 °C), double-serial dilutions of mouse sera in PBS containing 0.05% Tween 20 (PBS-T; 1 h at 37 °C) and goat anti-mouse IgG (Fc)-peroxidase conjugate (Sigma-Aldrich) diluted 1:4000 in PBS-T (1 h at room temperature). The different steps were separated by three washes with 0.9% NaCl, 0.05% Tween 20. Finally, the substrate solution –1 mM 2,2’-azino-di-(3-3-ethylbenzothiazoline-sulfonic acid) (ABTS; Sigma-Aldrich) and 2 mM H$_2$O$_2$ (Sigma-Aldrich) in 0.1 M citrate, pH 4.2- was added to the wells and the OD$_{405}$ readings were recorded on a Microplate Reader 550 (Bio-Rad, Hercules, USA) after 30 min incubation at room temperature. IgG isotypes were determined under the same conditions but using goat antibody IgG$_{1}$-, IgG$_{2a}$- or IgG$_{2b}$-peroxidase conjugates (Santa Cruz Biotechnology, Dallas, USA).

Antibody titers in serum were defined as the inverse of the highest serum dilution scoring an OD$_{405}$ value two times higher than that obtained with the blank (mean OD$_{405}$ of six wells in which serum was replaced by dilution buffer). The results for IgG were represented as means ± SD of the log of the titers obtained with five mice analyzed individually. The results concerning IgG isotypes were represented as means ± SD of the OD$_{405}$ values obtained with a 1/100 dilution of a pool of the five sera assayed in triplicate.

**Evaluation of cytokines in spleen and in splenocyte cultures**

Cytokine levels in the spleens of immunized mice were evaluated at 1, 3, 7, 14, 21 and 28 dpi (pre-challenge period in protection experiments). CHAPS (Sigma-Aldrich) was added (1% final concentration) to mouse spleens homogenized in Hanks balanced salt solution (Gibco-Life Technologies) (see vaccine persistence section) [26,27]. After a 1-h incubation at 4 °C, cell debris was removed by centrifugation and the supernatants were stored at −80 °C until analysis. The levels of interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), interleukin-1α (IL-1α), IL-10 and IL-12(p40) were quantified by sandwich ELISA with OptEIA™ Mouse sets specific to each cytokine, as instructed by the manufacturer (BD Biosciences, San Diego, USA) and described elsewhere [28]. The results for each vaccination group were expressed as means ± SD of the cytokine quantity (ng) detected in the spleens of five individual mice at each time-point.

Cytokine production was also evaluated, after stimulation with heat-inactivated \textit{B. ovis} PA whole cells, in cell cultures of splenocytes obtained from immunized mice at 28 dpi. Uniform single-cell suspensions were prepared by gentle disruption of spleens, as described previously [28]. Cells were suspended in complete RPMI medium (RPMI supplemented with 10% fetal calf serum, 4 mM L-glutamine, 1 mM sodium pyruvate, 0.05 mM 2-mercaptoethanol (Gibco-Life Technologies) and 100 $\mu$g/mL gentamicin), distributed in 24-well plates (4 x 10$^5$ cells/well in 1 mL) and cultured at 37 °C and a 5% CO$_2$ atmosphere. Splenocytes were stimulated by exposure to heat-inactivated (1 h at 65 °C) \textit{B. ovis} PA whole cells (10$^7$ CFU/
well), 10 μg/mL of the mitogen concanavalin A (Sigma-Aldrich) as a positive control of cell proliferation, or culture medium as a negative control. The stimulating agents were prepared in complete RPMI medium and added to each well in 100-μL volumes. After 72 h, the supernatants were harvested, centrifuged and stored at ~80 °C until use for cytokine quantification, performed as described above. Two wells were used for each experimental condition and mouse. The results for each vaccination group were expressed as means ± SD of the cytokine amount (ng/well) in the supernatants of splenocytes obtained from five individual mice. The results obtained with the positive and negative controls (concanavalin A and RPMI as stimulating agents, respectively) were as expected and are not shown.

Protection studies in mice
Mice inoculated with PBS (unvaccinated control), B. melitensis Rev 1 (10^5 CFU/mouse), B. ovis Δomp25d (10^7 CFU/mouse) or B. ovis Δomp22 (10^8 CFU/mouse) were challenged 28 days later with 10^5 CFU of virulent B. ovis PA. Three weeks after the challenge (49 days after immunization), the bacterial CFU numbers in spleen were counted in five mice from each experimental group, as described previously [19]. The CFU number of virulent B. ovis PA in mice vaccinated with B. melitensis Rev 1 (Strep-resistant strain; Table 1) was obtained by subtracting the CFU obtained in TSA-YE-HS-Strep medium from those obtained in the same medium without antibiotic. Similarly, differential counts in medium with and without Kan were used to determine the CFU of the challenge strain in the spleens of mice vaccinated with the B. ovis attenuated strains. Results were expressed as means ± SD (n = 5) of the log CFU/spleen of B. ovis PA for each vaccination group.

Statistical analyses
Statistical comparisons between means were performed using analysis of variance. The levels of significance of the differences between the experimental groups were determined with the post-hoc Fisher’s protected least significant differences (PLSD) test.

Results
Persistence of vaccine strains in spleen
Spleen weight and bacterial counts were determined at several pi time-points in mice inoculated with B. melitensis Rev 1, B. ovis Δomp25d, and B. ovis Δomp22 (retrospectively determined doses of 0.9 × 10^5, 1.2 × 10^7, and 0.80 × 10^8 CFU/mouse, respectively).

Under the assay conditions, spleen colonization by B. melitensis Rev1 and B. ovis Δomp25d was quite similar, with a peak of about 7 log CFU/spleen at 1 week pi and a progressive decrease in bacterial counts thereafter until the end of the experiment on day 49 pi (Figure 1A). However, while the classic B. melitensis Rev 1 vaccine was detected in most of the animals on days 28 and 49 pi, all mice inoculated with the B. ovis Δomp25d mutant had cleared the infection by day 49 pi (according to the detection limit of the technique) and only 1 out of five mice showed bacteria in its spleen at day 28 pi. With the B. ovis Δomp22 attenuated mutant, the highest level of spleen colonization extended from day 3 to day 21 pi and was 2 log units lower (about 5 log CFU/spleen) than that obtained with the two other vaccines on day 7 pi. Thereafter, B. ovis Δomp22 behaved similarly to the other vaccines (Figure 1A).

Regarding spleen weight (Figure 1B), the two B. ovis attenuated mutants did not induce significant inflammation of the spleen along the assay, while the B. melitensis Rev 1 classic vaccine induced a strong transient splenomegaly, reaching its highest level at 14 dpi. At that moment, spleen weight in the mice inoculated with B. melitensis Rev 1 was about 4 times higher than that observed in mice inoculated with the B. ovis mutants (Figure 1B).

Antibody response against B. ovis induced by the vaccines
The levels of serum IgG able to react with whole B. ovis cells in i-ELISA were evaluated up to day 28 pi (pre-challenge period in the protection experiments) in mice inoculated, as described for the persistence assay, with PBS (negative control group) or each of the three attenuated vaccines.

In mice immunized with the two B. ovis attenuated mutants, the IgG response against whole B. ovis cells became evident by day 7 pi and increased progressively thereafter until the end of the experiment (Figure 2A). On days 7 and 14 pi, IgG titers were higher in mice immunized with B. ovis Δomp22 than in those immunized with B. ovis Δomp25d, but they reached similar levels by day 28 pi (Figure 2A). In comparison, the IgG response in mice immunized with B. melitensis Rev 1 was delayed and weaker, since detectable titers appeared on day 14 pi and were lower than those observed with the B. ovis vaccines at all time-points checked (Figure 2A). Inside each vaccination group, no important differences were detected in the proportion of the IgG1, IgG2a and IgG2b isotypes (Figure 2B-D).

Spleen cytokines in vaccinated mice
The cytokine profile in spleen was also evaluated until day 28 pi in mice inoculated, as described for the persistence assay, either with PBS or with the attenuated strains.

The highest levels of IFN-γ, TNF-α, IL-1α, IL-10 and IL-12(p40) in spleen were detected in mice immunized with B. melitensis Rev 1 (Figure 3). In this group of mice,
all cytokines, except IL-10, were present in high levels on days 7 and 14 pi, with a production peak on day 14 pi, and a decrease thereafter until day 28 pi, when all cytokines had levels similar to those detected in mice inoculated with PBS (Figure 3). IL-10 production in the Rev 1-vaccinated mice followed a similar pattern but with a delay of 7 days, the highest levels being detected on days 14 and 21 pi (Figure 3D). Whereas TNF-α and IL-10 scored the lowest levels (about 1.5 and 2 ng/spleen, respectively), the strongest response was obtained with IL-1α and IL-12(p40) (maximum levels about 10 ng/spleen) followed by IFN-γ (5 ng/spleen).

Although to a lesser extent than B. melitensis Rev 1, B. ovis Δomp25d also induced the production in spleen of all cytokines tested (Figure 3), with the exception of IL-10 (Figure 3D). A peak of cytokine production was observed on day 7 pi, which was followed by a progressive decrease until day 28 pi, when no differences between the mice inoculated with B. ovis Δomp25d and the PBS-inoculated mice were observed (Figure 3).

In general, the mice immunized with B. ovis Δomp22 did not show statistically significant differences in cytokine production in spleen when compared with mice inoculated with PBS (Figure 3). The exception was IL-12 (p40) on day 7 pi, whose concentration in spleen was slightly higher in mice inoculated with B. ovis Δomp22 (Figure 3E).

Cytokine secretion by splenocytes of vaccinated animals in response to a stimulus with B. ovis PA whole cells
Mice were immunized with B. melitensis Rev1, B. ovis Δomp25d, B. ovis Δomp22 (retrospectively determined doses of 0.9 × 10^5, 1.1 × 10^7, and 1.4 × 10^8 CFU/mouse, respectively) or with PBS.

To evaluate the ability of spleen cells of the vaccinated animals to respond to a second stimulus by antigen,
Splenic mononuclear cells obtained on the 28th day post-infection (pi) were stimulated with heat-inactivated B. ovis PA and the cytokines secreted were quantified after 72 h of incubation (see Materials and Methods).

Splenocytes from mice immunized with B. melitensis Rev 1 or with the two B. ovis attenuated mutants secreted high levels of IFN-γ (ranging between 97 and 223 ng/well), which was the most abundant cytokine, in response to the second antigen stimulus with B. ovis PA (Figure 4A). By contrast, IFN-γ production by splenocytes obtained from mice inoculated with PBS was comparatively weak (about 5 ng/well; \( P < 0.0005 \)) (Figure 4A).

The three attenuated vaccines induced the secretion of TNF-α by stimulated spleen cells to a similar extent and in amounts that were two times higher (\( P < 0.05 \)) than those detected in the group inoculated with PBS (Figure 4B). Regarding the production of IL-1α, no differences were found between the stimulated splenocytes of mice immunized with B. melitensis Rev 1 and those of the control mice inoculated with PBS (Figure 4C). In contrast,
the production of IL-1α in the B. ovis Δomp25d and B. ovis Δomp22 vaccination groups was about four times and three times higher, respectively (Figure 4C).

A strong IL-10 response was detected in stimulated spleen cells of mice immunized with the B. melitensis Rev 1 classic vaccine (Figure 4D), while the spleen cells of mice vaccinated with the two B. ovis attenuated strains behaved similarly to those obtained from mice immunized with PBS (Figure 4D). Regarding the secretion of IL-12 (p40) by stimulated spleen cells, no statistically significant differences were found between the mice immunized with the attenuated Brucella strains and the control mice immunized with PBS (Figure 4E).

**Protective efficacy of the attenuated mutants against B. ovis infection**

Mice immunized with PBS (negative immunization control), B. melitensis Rev 1, B. ovis Δomp25d or B. ovis Δomp22 (retrospectively determined doses of 0.9 × 10⁸, 1.1 × 10⁷, and 1.4 × 10⁸ CFU/mouse, respectively) were challenged 28 days after immunization with virulent B. ovis PA (retrospectively determined dose of 0.9 × 10⁵ CFU/mouse). Bacteria were counted in spleen 3 weeks after the experimental infection.

The B. melitensis Rev 1 classic vaccine and the two B. ovis attenuated strains conferred similar protection (P > 0.05) against a challenge with B. ovis. When compared to mice inoculated with PBS, the three attenuated vaccines reduced spleen colonization of virulent B. ovis PA in the order of 3 log units (Figure 5). Only the challenge strain was isolated in mice vaccinated with B. ovis Δomp25d while the B. ovis Δomp22 and B. melitensis Rev 1 vaccine strains were detected in 3 out 5 mice.

**Discussion**

B. melitensis Rev 1 is considered the best vaccine available against B. ovis infection but it has important drawbacks that constrain its use for the specific prophylaxis of brucellosis caused by B. ovis [3-7]. Since live attenuated vaccines have provided the best results in terms of protection against infections caused by other Brucella species [29-31], it is to be expected that an attenuated strain would also be the best choice for a vaccine targeting B. ovis infection. Smooth vaccine strains other than B. melitensis Rev 1 (i.e. B. abortus S19 or B. suis S2) would not avoid the interference with the serological diagnosis of smooth strain infections and, consequently, are not suitable vaccines. Theoretically, rough B. abortus RB51 would offer a good alternative because interference with diagnosis would be minimized. However, in spite of the rough surface phenotype of B. abortus RB51, the risk of inducing O-PS antibodies cannot be ignored owing to the presence of small amounts of O-PS in its cytoplasm [32] and, more importantly, this attenuated vaccine proved to be inefficient in preventing against B. ovis infection in rams [6]. Moreover, although some cases of heterologous protection have been reported, in livestock homologous Brucella spp. are usually more protective than heterologous Brucella spp. [31]. Accordingly, a B. ovis attenuated strain would likely be the most interesting candidate to develop a specific vaccine against ram contagious epididymitis. This hypothesis also seems to be supported by the fact that B. ovis displays significant differences in surface topology, outer membrane properties and antigenic behavior when compared to other Brucella species [2,21,33-35].

Although a recent work has reported the ability of a B. ovis attenuated mutant to induce an immune response in a natural host [36] and another work has analyzed the protective activity of a B. ovis mutant in a murine model [37], the potential of attenuated B. ovis strains as vaccines remains almost unexplored. Two B. ovis mutants defective in Omp25d and Omp22 surface protein, have previously been shown to display attenuated virulence in a mouse model [19,38] and in the present work they were evaluated as homologous live attenuated vaccines, in comparison to heterologous B. melitensis Rev 1, for the prophylaxis of B. ovis infection.

In a previous study, when inoculated at a dose of 5 × 10⁶ CFU/mouse the Δomp22 mutant of B. ovis PA was almost undetectable in spleen from week 1 pi [19], while the Δomp25d mutant displayed a more moderate attenuation, with even higher spleen colonization during the initial stages of infection than that of the parental strain but with a rapid clearance thereafter [19]. However,
when the immunization dose was increased to $1 \times 10^8$ CFU/mouse, even though maximum bacterial counts were 2 log units lower than those of *B. melitensis* Rev 1, the persistence in spleen of *B. ovis* Δomp22 was similar to that observed for the Rev 1 vaccine (Figure 1A) at the dose commonly used for protection studies in mouse models [22] and also in this work. The increase in the inoculation dose of the Δomp25d mutant led to a spleen growth curve that exhibited the same pattern as that observed for the classic vaccine *B. melitensis* Rev 1 under our assay conditions of (Figure 1A). Accordingly, the requirement of a certain degree of persistence considered necessary for an efficacious vaccine against *Brucella* spp. [39,40] seems to have been accomplished with the *B. ovis* Δomp25d and Δomp22 mutants, since their evolution in spleen was similar to that observed with a recognized control of vaccine efficacy against *B. ovis* (Figure 1A).

*B. melitensis* Rev 1 induced a strong inflammatory response in spleen, this response reaching its highest level of intensity on day 14 pi, while *B. ovis* Δomp25d, with a spleen colonization profile similar to that of *B. melitensis* Rev 1 (Figure 1A), and *B. ovis* Δomp22 only elicited a moderate degree of splenomegaly (Figure 1B). Spleen inflammation in the mice inoculated with *B. melitensis* Rev 1 correlated with the high levels of cytokines detected in this organ, since with the exception of IL-10 all the cytokines peaked on day 14 pi (Figure 3), concomitantly with spleen weight (Figure 1B). In these mice, the maximum spleen levels of IL-10 were reached one week later (Figure 3D), which, considering the anti-inflammatory role proposed for this cytokine, could reflect a mechanism aimed at counterbalancing the deleterious effects in the host derived from the exacerbated inflammatory response [41,42]. This hypothesis seems to be supported by the fact that the increase in IL-10 observed in mice vaccinated with *B. melitensis* Rev 1 (Figure 3D) was accompanied by a striking reduction in both spleen weight (Figure 1B) and the amount of the other cytokines analyzed (Figure 3). The reduction in cytokine levels continued until day 28 post-vaccination, when they reached the basal values observed in mice inoculated with PBS or with the *B. ovis*-derived vaccines (Figure 3). Since the challenge with virulent *B. ovis* PA was performed at that moment, the protection afforded by the vaccines cannot be attributed to residual cytokines from the primary immunization. However, vaccination with *B. melitensis* Rev 1 or the attenuated Δomp22 and Δomp25d strains of *B. ovis* induced a memory immune response that could be activated by *B. ovis* cells and that was evidenced by the pattern of cytokine secretion when splenocytes obtained from vaccinated mice were re-stimulated ex vivo with killed *B. ovis* PA whole cells (Figure 4).

The strong inflammatory response -revealed by the prominent increase in spleen weight and cytokine levels-detected in the spleens of mice vaccinated with *B. melitensis* Rev 1 with respect to that induced by the *B. ovis* vaccines (Figures 1B and 2) would initially predict a better protective activity for the former vaccine. However, the protection conferred by *B. ovis* Δomp25d and Δomp22 against an experimental *B. ovis* infection was equivalent to that of *B. melitensis* Rev 1 (Figure 5), and several reasons can be invoked to explain this. First, the higher response of antibodies able to bind to *B. ovis* whole cells detected in mice immunized with the *B. ovis*-derived vaccines (Figure 2) constitutes an advantageous characteristic of the homologous vaccines over *B. melitensis* Rev 1, since a more prominent role for antibodies than for T lymphocytes has been identified in protective immunity against *B. ovis* [43]. Second, the level of IFN-γ, which is known to play a critical role in the control of primary and secondary *Brucella* infections [44,45], secreted by spleen cells from immunized mice in response to exposure to *B. ovis* whole cells was remarkably high (ranging between 97 and 223 ng/well) in the three vaccination groups (Figure 4A). Third, splenocytes from mice vaccinated with the *B. ovis*-derived vaccines secreted more IL-10, which has been shown to be a potent enhancer of CD4 and CD8 T cell responses to antigen [46], than splenocytes obtained from mice vaccinated with *B. melitensis* Rev 1 or non-vaccinated mice (Figure 4C). Finally, re-stimulated spleen cells of mice vaccinated with the *B. ovis* attenuated mutants did not differ from those obtained from non-vaccinated mice regarding the production of IL-10, while vaccination with *B. melitensis* Rev 1 induced an intense IL-10 response in re-stimulated splenocytes. Considering the anti-inflammatory role proposed for this cytokine [41,42], this might also constitute an advantage for the *B. ovis* attenuated vaccines.

Some of these valuable characteristics of *B. ovis* Δomp25d and Δomp22 are probably related to a more specific immune response induced when homologous vaccines are used. Despite the antigenic differences described for *B. ovis* in comparison with other *Brucella* species, only a moderate degree of antigenic diversity is expected between *B. ovis* and *B. melitensis* species, only a moderate degree of DNA identity shared by them [47]. However, S-LPS is the major immunodominant antigen in smooth strains such as *B. melitensis* Rev 1 [48,49], while R-LPS and OMPs are immunodominant components in rough *B. ovis* that lack S-LPS [50]. Accordingly, an important percentage of the immune response developed after vaccination with *B. melitensis* Rev 1 would probably not be effective against later infection by *B. ovis*. By contrast, the immune response triggered by the *B. ovis* attenuated vaccines would target homologous antigens during a *B. ovis* infection and would theoretically be more efficient in controlling the disease. Another positive aspect of *B. ovis* Δomp25d and Δomp22 is that their protective activity is accompanied by a limited
degree of splenomegaly, suggesting that these vaccines would prevent undesirable effects associated with inflammation in the host, as described for the classic vaccines B. abortus S19 and B. melitensis Rev 1 [51,52].

According to the results reported here, the attenuated strains B. ovis Δomp25d and Δomp22 induce a solid immune response, with mixed Th1 and Th2 components, able to control later infection by B. ovis as efficiently as vaccination with heterologous B. melitensis Rev 1. Considering the drawbacks of vaccination with B. melitensis Rev 1 [5,8,9], especially for the prophylaxis of B. ovis infection, the attenuated vaccines analyzed here constitute a promising alternative as specific vaccines against ram contagious epididymitis that merits further evaluation in the natural host and the analysis of alternative formulations that might increase protective activity, such as microencapsulation for sustained release, as described for other Brucella vaccines [51,52].

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

PS, CT, LFL and NV wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgments

We thank Nicholas Skinner for supervising the English version of this manuscript and the staff of the animal experimentation facilities of the University of Salamanca for their helpful collaboration. Financial support to Sancho et al. Veterinary Research 2014, 45:61 Page 9 of 10 this work was provided by the Ministerio de Economía y Competitividad of Spain.

Received: 30 March 2014 Accepted: 23 May 2014

References

1. Burgess GW: Ovine contagious epididymitis: a review. Vet Microbiol 1982, 7:551–579.

2. Vizcaíno N, Cloeckaert A: Biology and genetics of the Brucella outer membrane. In Brucella molecular microbiology and genomics. Edited by López-Góri I, O’Callaghan D. Norfolk, UK: Caister Academic Press; 2012:133–161.

3. OIE: Chapter 2.7.9. Ovine epididymitis (Brucella ovis). In Manual of diagnostic tests and vaccines for terrestrial animals; 2013. [http://www.oie.int/en/international-standard-setting/terrestrial-manual/access-online/].

4. Blasco JM: Brucella ovis. In Animal brucellosis. Edited by Nielsen K, Duncan JR. Boca Ratón, FL, USA: CRC Press; 1990:351–575.

5. OIE: Chapter 2.7.2. Caprine and ovine brucellosis (excluding Brucella abortus infection in rams). In Manual of diagnostic tests and vaccines for terrestrial animals; 2013. [http://www.oie.int/en/international-standard-setting/terrestrial-manual/access-online/].

6. Blasco JM: A review of the use of B. melitensis Rev 1 vaccine in adult sheep and goats. Prev Vet Med 1997, 31:275–283.

7. Jiménez de Bagués MP, Barberán M, Marín CM, Blasco JM: The Brucella abortus REV1 vaccine does not confer protection against Brucella ovis in rams. Vaccine 1995, 13:301–304.

8. Ridler AL, West DM: Control of Brucella ovis infection in sheep. Vet Clin North Am Food Anim Pract 2011, 27:61–66.

9. Alton GG, Jones LM, Angus RD, Verger JM: Techniques for the brucellosis laboratory. Paris, France: Institut National de la Recherche Agronomique; 1988.

10. Grillo MI, Bossary N, Blasco JM: In vitro markers and biological activity in mice of seed lot strains and commercial Brucella melitensis Rev 1 and Brucella abortus B19 vaccines. Biologics 2000, 28:119–127.

11. Blasco JM, Gamazo C, Winter AJ, Jiménez de Bagués MP, Marín C, Barberán M, Moriyón I, Alonso-Urmeneta B, Díaz R: Evaluation of whole cell and subcellular vaccines against Brucella ovis in rams. Vet Immunol Immunopathol 1993, 37:257–270.

12. Da Costa Martins R, Iraiche JM, Blasco JM, Muñoz MP, Marín CM, Grillo MI, De Miguel MJ, Barberán M, Gamazo C: Evaluation of particulate acellular vaccines against Brucella ovis infection in rams. Vaccine 2010, 28:3038–3046.

13. Estein SM, Fiorentino MA, Paolicchi FA, Clauasse M, Manzana J, Cassatario J, Giambartolomei GH, Coria LM, Zylberman V, Fossati CA, Kijek R, Goldbaum FA: The polymeric antigen BLSomp31 confers protection against Brucella ovis infection in rams. Vaccine 2009, 27:604–611.

14. Estein SM, Cassatario J, Vazcaino N, Zygmunt MS, Cloeckaert A, Bowden PA: The recombinant Omp31 from Brucella melitensis alone or associated with rough lipopolysaccharide induces protection against Brucella ovis infection in BALB/c mice. Microbes Infect 2003, 5:85–93.

15. Cassatario J, Pasquevich KA, Estein SM, Lamplagne DA, Zwerdling A, de la Barrera S, Bowden R, Fossati CA, Giambartolomei GH, Goldbaum FA: A DNA vaccine coding for the chimeric BLSomp31 induced a better degree of protection against B. ovis and a similar degree of protection against B. melitensis than Rev.1 vaccination. Vaccine 2007, 25:5958–5967.

16. Cassatario J, Velkovsky CA, de la Barrera S, Estein SM, Bruno L, Bowden R, Pasquevich KA, Fossati CA, Giambartolomei GH: A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response. Infect Immun 2005, 73:6537–6546.

17. Estein SM, Choves PC, Fiorentino MA, Cassatario J, Paolicchi FA, Bowden RA: Immunogenicity of recombinant Omp31 from Brucella melitensis in rams and serum bactericidal activity against B. ovis. Vet Microbiol 2004, 102:203–213.

18. Nicoletti P: Brucellosis: past, present and future. Philosc 2010, 31:21–32.

19. Caro-Hernández P, Fernández-Lago L, de Miguel MJ, Martín-Martin AJ, Cloeckaert A, Grillo MI, Vázcano N: Role of the Omp25/Omp31 family in outer membrane properties and virulence of Brucella ovis. Infect Immun 2007, 75:4050–4061.

20. Salhi I, Boigegrain RA, Machold J, Weise C, Cloeckaert A, Rueot B: Characterization of new members of the group 3 outer membrane protein family of Brucella spp. Infect Immun 2003, 71:5426–5432.

21. Vazcaino N, Caro-Hernández P, Cloeckaert A, Fernández-Lago L: DNA polymorphism in the omp25/omp31 family of Brucella spp.; identification of a 1.7-kb inversion in Brucella cetaceae and of a 15.1-kb genomic island, absent from Brucella ovis, related to the synthesis of smooth lipopolysaccharide. Microbes Infect 2004, 6:821–834.

22. Grillo MI, Blasco JM, Gorvel JP, Moriyón I, Moreno E: What have we learned from brucellosis in the mouse model? Vet Res 2012, 43:29.

23. OIE: Chapter 2.7.2. Caprine and ovine brucellosis (excluding Brucella ovis). In Manual of diagnostic tests and vaccines for terrestrial animals; 2013. [http://www.oie.int/en/international-standard-setting/terrestrial-manual/access-online/].

24. Silva TM, Costa EA, Paixão TA, Tsolis RM, Santos RL: Laboratory animal models for brucellosis research. J Biomed Biotechnol 2011, 2011:518323.

25. Bantino MB, Grillo MI, Muñoz PM, Jacques I, Gonçalvez D, de Miguel MJ, Marín CM, Barberán M, Letessson JL, Gorvel JP, Moriyón I, Blasco JM, Zygmunt MS, Rough mutants defective in core and O-poly saccharide synthesis and export induce antibodies reacting in an indirect ELISA with smooth lipopolysaccharide and are less effective than Rev 1 vaccine against Brucella melitensis infection of sheep. Vaccine 2009, 27:1741–1749.

26. Fernández-Lago L, Monte M, Chordi A: Endogenous gamma interferon and interleukin-10 in Brucella abortus 2308 infection in mice. FEMS Immunol Med Microbiol 1996, 15:109–114.

27. Fernández-Lago L, Rodríguez-Tarazona E, Vazcaino N: Differential secretion of interleukin-12 (IL-12) subunits and heterodimeric IL-12p70 protein by CD-1 mice and murine macrophages in response to intracellular infection by Brucella abortus. J Med Microbiol 1999, 48:1065–1073.

28. Fernández-Lago L, Ordúña A, Vazcaino N: Reduced interleukin-18 secretion in Brucella abortus 2308-infected murine peritoneal macrophages and in spleen cells obtained from B. abortus 2308-infected mice. J Med Microbiol 2005, 54:527–531.

29. Godfroid J, Scholz HC, Barber T, Nicolas C, Wattiau P, Fretin D, Whatmore AM, Cloeckaert A, Blasco JM, Moriyón I, Sægeman C, Muma J, Al Dahouk S, Neubauer H, Letesson JJ: Brucellosis at the animal/ecosystem/human interface at the beginning of the 21st century. Vet Res 2011, 42:107–118.
and confers protection against wild-type challenge in BALB/c mice when delivered in a sustained-release vehicle. Infect Immun 2009, 77:877–884.

52. Arenas-Gamboa AM, Ficht TA, Kahl-McDonagh MM, Rice-Ficht AC: Immunization with a single dose of a microencapsulated Brucella melitensis mutant enhances protection against wild-type challenge. Infect Immun 2008, 76:2448–2455.

Submit your manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit